Grace Therapeutics files prospectus for 4.762m share sale

0 min read | Published on 25 Aug 2026, 01:47 AM |Updated on 25 Aug 2026, 01:47 AM

Reviewed by

Riya DScanX News Team

Key Highlights

Grace Therapeutics Inc. filed a Form S-3 with the SEC. The offering includes 4.762 million common shares. Shares are being sold by existing shareholders. No proceeds will go to the company. Filing is available via the SEC EDGAR system.

*this image is generated using AI for illustrative purposes only.

Grace Therapeutics Inc. filed a registration statement with the US Securities and Exchange Commission to offer 4.762 million common shares on behalf of selling shareholders.

The filing, submitted under Form S-3, indicates that the shares are being offered by existing holders rather than the company itself. The document is accessible via the SEC’s Electronic Data Gathering, Analysis, and Retrieval system.

Filing Details

Metric	Value
Company	Grace Therapeutics Inc.
Shares Offered	4.762 million
Type	Common Shares
Seller	Selling Shareholders
Regulator	US Securities and Exchange Commission

The filing does not disclose the identity of the selling shareholders or the intended use of proceeds, as the transaction involves secondary sales by existing investors.

How might the potential dilution from these 4.762 million shares impact Grace Therapeutics' stock price and market capitalization in the near term?

Which institutional investors or early backers are likely behind this secondary sale, and what does their exit strategy signal about their confidence in the company's pipeline?

Will this filing coincide with or influence the timing of Grace Therapeutics' upcoming clinical trial data releases for its lead drug candidates?

Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen

0 min read | Published on 13 Aug 2026, 07:52 PM |Updated on 13 Aug 2026, 07:52 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Grace Therapeutics reported a Q1 EPS of $(0.91), missing the $(0.18) estimate by 405.56%. This signifies a 333.33% widening of losses compared to the $(0.21) EPS from the prior year period.

*this image is generated using AI for illustrative purposes only.

Grace Therapeutics (NASDAQ: GRCE) reported a quarterly loss of $(0.91) per share for the first quarter, significantly missing the analyst consensus estimate of $(0.18). The miss represents a deviation of 405.56% against the expected figure.

Compared to the same period last year, the company’s per-share loss widened substantially. The current quarter’s loss of $(0.91) marks a 333.33% increase over the $(0.21) per-share loss recorded in the prior year’s corresponding quarter.

What the Numbers Show

The divergence between the actual loss and the consensus estimate highlights a significant variance in market expectations versus reported performance. While the source data does not provide revenue or operational expense breakdowns to isolate the driver of this miss, the magnitude of the estimate miss (405.56%) suggests that the actual burn rate or one-off charges were considerably higher than what analysts had priced into their models.

Furthermore, the year-over-year expansion in losses indicates that the company’s path to profitability remains under pressure, with the per-share deficit more than quadrupling compared to the previous fiscal period.

What specific operational expenses or one-off charges contributed to the 405% miss against analyst consensus estimates?

How does the widened loss impact Grace Therapeutics' current cash runway and potential need for dilutive capital raises?

Will Grace Therapeutics adjust its full-year guidance to reflect the significantly higher burn rate observed in Q1?